Peroxisome Proliferator-Activated Receptors in HBV-Related Infection by Dubuquoy, Laurent et al.
Hindawi Publishing Corporation
PPAR Research
Volume 2009, Article ID 145124, 6 pages
doi:10.1155/2009/145124
Review Article
Peroxisome Proliferator-Activated Receptors in
HBV-Related Infection
LaurentDubuquoy,1,2,3 AlexandreLouvet,1,2,3 AntoineHollebecque,1,2,3
Philippe Mathurin,1,2,3 andS´ ebastien Dharancy1,2,3
1Institute National de la Sant´ ee td el ar e c h e r c h eM ´ edicale INSERM, U795, 59037 Lille, France
2University Lille 2, 59045 Lille, France
3Service des Maladies de l’Appareil Digestif et de la Nutrition, Hˆ opital Huriez, CHRU Lille,
59037 Lille, France
Correspondence should be addressed to S´ ebastien Dharancy, s6@chru-lille.fr
Received 1 October 2008; Accepted 18 February 2009
Recommended by Lawrence Serfaty
Thirty years after its discovery, the hepatitis B virus (HBV) still remains a major global public health problem. Worldwide, two
billion subjects have been infected, 350 million have a chronic infection and more than 600000 die annually of HBV-related liver
disease or hepatocellular carcinoma; new infections occur because of the presence of a large reservoir of chronic carriers of the
virus. Since a decade several studies describe the interrelations between HBV and nuclear receptors and more particularly the
peroxisome proliferator-activated receptors (PPARs). After a brief introduction, this review will make a rapid description of HBV
incidence and biology. Then a report of the literature on the role of PPARs on viral transcription and replication will be developed.
Finally, the role of HBV on PPARγ expression and activity will be discussed. Concluding remarks and perspectives will close this
review.
Copyright © 2009 Laurent Dubuquoy et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Hepatitis B virus (HBV) infection is a major public health
problem with approximately 350 million people chronically
infected but the prevalence of HBV infection and patterns
of transmission vary greatly throughout the world. Fifteen
percent to 40% of HBV-infected patients will develop
cirrhosis, liver failure, and hepatocellular carcinoma (HCC)
[1]. Hepatitis B virus was considered to be not directly
cytopathic, and the development of HCC in individuals with
chronic HBV infection is a multistage, multifactorial process
including the interaction between host and environmental
factors. However, a recent study suggested that elevated serum
HBV DNA level (≥10000copies/mL) was a risk predictor of
HCC independent of hepatitis B e antigen (HBeAg), serum
alanine aminotransferase level, and liver cirrhosis suggesting
that HVB proteins themselves may have direct eﬀect on cellular
functions [2].
Recent data suggested the implication of nuclear hor-
mone receptor and especially of the retinoid X recep-
tors (RXRs) and peroxisome proliferator-activated recep-
tors (PPARs) in the transcription and the replication of
the HBV. The peroxisome proliferator-activated receptors
(PPARs) α, β/δ,a n dγ are members of the nuclear recep-
tor superfamily activated by fatty acids and involved in
the transduction of metabolic and nutritional signals into
transcriptional responses [3, 4]. Among these transcription
factors, PPARα/γ together with their obligate partner the
RXR are three main nuclear receptors expressed in the liver
[5–7]. However, despite strong expression in the liver, proof
of an eventual role of PPARs in hepatic disease remains
limited to the link between hepatic tumorigenesis and
chronic administration of PPARα activators in rodents [8],
the development of extensive hepatic steatosis in response
to fasting and delayed liver regeneration in PPARα knock-
out mice [9, 10], impaired expression of PPARα in a murine
model of alcoholic liver diseases [11], and impaired liver2 PPAR Research
expression of PPARα inﬂuenced by the HCV core protein
during chronic hepatitis C virus infection [12].
This review will ﬁrst describe the importance of HBV
infection worldwide and the biology of the virus. Then the
interactions between PPARs and HBV will be developed to
provide a precise picture of the potential role of PPARs in
HBV pathophysiology.
2.HepatitisBVirus:IncidenceandPrevalence
Approximately 2 billion people have been exposed to the HBV
and 350 million people are chronically infected with the virus.
Each year over 1 million people die from HBV-related liver
disease. The chapter below will expose the incidence and
prevalence of this huge public health problem worldwide.
TheprevalenceofHBVinfectionvariesdependingonthe
geographical area. In the Far East, the Middle East, Africa,
and parts of South America, the prevalence is high, with
hepatitis B surface antigens (HBsAgs) rates ranging from
8% to 15% [13]. In regions of high HBsAg endemicity,
serologic evidence of prior HBV infection (anti-HBc and/or
anti-HBs Ag) is almost universal in subjects without active
infection. As a general rule, in these areas with high
HBV endemicity the source of infection is mainly through
perinatal transmission from the chronically infected mother
or through infection during early childhood.
Areas of intermediate prevalence (2–7%) include Japan,
parts of South America, Eastern and Southern Europe,
and parts of central Asia. Areas with low HBV endemicity
(prevalence of chronic infection <2%) include Northwestern
Europe, North America, and Australia [14]. The source of
infection in these areas is mainly through sexual contacts
and needle sharing among injecting drug users, with a peak
incidence in the 15–25-year-old age group.
Globally the incidence of acute HBV infection has been
falling in the last decade, due to changes in behavior (e.g.,
increase in safe sexual practices related to HIV education
eﬀorts) and, to a lesser extent, to the introduction of
eﬀective vaccination programs [15]. Transmission of HBV
via transfusion of blood and plasma-derived products has
been eliminated in most countries through donor screening
for HBsAg and viral inactivation procedures.
3. ViralStructure,GenomicOrganization
and Replication
HBV is a member of the family of the hepadnaviridae,
hepatotropic DNA viruses. Characteristics of these viruses are
as follows: a partially double-stranded DNA, with an outer
lipoprotein envelope and an inner nucleocapsid or core bearing
the viral genome; a polymerase with reverse transcription
activity; the massive overproduction of viral envelope proteins
(e.g., HBsAg), and a relative but not absolute hepatotropism.
The following chapter will brieﬂy describe the viral structure,
genomic organization and replication mode of the HBV.
HBV virions are 42nm double-shelled particles. The
genome contains four open reading frames (ORFs) (S, P, C,
andX)thatencodefourmajorproteins(surface,polymerase,
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Figure 1: HBV virion and genomic organization. The HBV virion
is composed of a viral envelop that contains the surface proteins,
which are of diﬀerent lengths (L, M, and S). The nucleocapsid or
core wraps the viral DNA. The viral genome contains four open
reading frames, the S that encodes for the surface protein (red), P
thatencodesfortheviralpolymerase(blue),preCandCthatencode
for the core (yellow) and X that encodes for the X protein (green).
core, and X protein, resp.) (Figure 1). The major abundant
proteinonthevirussurfaceistheHBsAgorSprotein,24kDa
in size. In the viral envelope there are two other proteins,
the L—involved in binding the virus to a receptor on the
hepatocyte surface—and the M protein, whose function is
unknown.
The 27nm nucleocapsid is an icosahedral symmetric
structure containing 180 or 240 copies of the viral core (C)
protein [16, 17], known as hepatitis B core antigen (HBcAg).
The nucleocapsid contains the viral genome (Figure 1), a
relaxed circular molecule that consists of a 3.2kB minus
strand and a smaller, complementary DNA (plus strand)
of variable length. Circularity of HBV is maintained by
hydrogen bonds between 250bp at the two 50 ends of the
plus and minus strands. The 50 ends of the DNA strands
are each linked covalently to additional structures, essential
for the initiation of DNA synthesis, that is, the polymerase
and an oligo RNA. The viral polymerase is encoded by the
P gene of the virus and is implicated in the synthesis of both
strands of viral DNA through a reverse transcriptase (protein
P) enzyme (RT). This RT shares sequence similarities with
retroviral RT; the latter has been used in the development of
antiviral drugs against HBV.
In addition to complete virions, HBV-infected hepato-
cytesproduceingreatexcesstwodistinctsubvirallipoprotein
particles: the spheres, containing primarily the S protein,
and the ﬁlaments, less numerous, rich in L protein. As these
subviral particles contain only envelope glycoproteins and
host-derived lipids, but not viral DNA; they are not infec-
tious; nevertheless, they strongly stimulate the production
of neutralizing anti-HBs antibodies. The overproduction of
these particles makes it easy to diagnose HBV infection by
the detection of the surface antigen in the blood.
Little is known about the earliest steps in the HBV life
cycle.Virionbindingtohepatocytesismediatedbya180kDa
host protein identiﬁed as a member of the carboxypeptidase
family [18]; antibodies against this protein block viral
infection [19]. After direct membrane fusion uncoating of
the virus allows the presentation of the nucleocapside to thePPAR Research 3
P
S
preC C
X
ENH I ENH II
HRE
(HNF4)
HRE
(HNF4, PPARα/RXRα,
COUP-TF1, TR2)
HRE (HNF4, PPARα/RXRα,
COUP-TF1, TR2)
Figure 2: NR regulatory region in HBV genome. Schematic diagram of the HBV genome. The viral polymerase (P), surface proteins (S),
precore (preC), core (C), and X protein (X) open reading frames are indicated by open rectangular boxes. Enhancers (ENHs) I and II
are indicated by grey rectangular boxes. The hormone response elements (HREs) are indicated by small black rectangular boxes. Nuclear
receptors that can bind these HREs are indicated into brackets.
cytosol. The naked viral core migrates to the nucleus where
the viral genome is repaired to a covalently closed circular
form (cccDNA). This cccDNA is transcribed by host RNA
polymerase II to generate genomic and subgenomics stable
RNAs. All viral RNAs are transported to the cytoplasm for
translation yielding the viral envelope, core and preC, viral
DNA polymerase, and X proteins. Finally, nucleocapsids are
assembled in the cytosol; assembly requires the binding of
viral polymerase (P) to a selective structure located at the
5
 end of the genomic RNA. Once the P-RNA complex is
formed,RNApackagingandreversetranscriptionbegin.The
replication of HBV requires an RNA intermediate followed
by the synthesis of viral DNA by RT [20]. After replication is
completed, viral cores are transported back into the nucleus,
where they are either converted to cccDNA to maintain a
stable intranuclear pool of transcriptional templates or more
frequently, bud into the endoplasmic reticulum or Golgi
apparatus; in this site nucleocapsidic particles are wrapped
in the envelope proteins (surface, L, and M) and ﬁnally
exported from the cell as full virions by vesicular transport
[21].
4. Impact of PPAR on Viral Transcription
and Replication
StudiesinhepatomacelllineHepG2andstudiesonatransgenic
m o u s em o d e lf o rH B Vh a v ep r o v i d e de v i d e n c ef o rar o l eo f
PPARS in controlling viral transcription and replication.
HBV has a partially double-stranded DNA genome and
replicates through an RNA intermediate. After infecting host
liver cells, there are four HBV transcripts from four diﬀerent
viral promoters: Core, SPI, SPII, and X promoter. The ﬁrst
studiesthathavelinkedPPARandHBVhaveshownthepres-
enceofhormoneresponseelements(HREs)inthepromoters
of HBV genome (Figure 2). In the dediﬀerentiated hepatoma
cell line, HepG2, it was found that the nucleocapsid and
large surface antigen promoters were transactivated in the
presence of hepatocyte nuclear factor 4 (HNF4) whereas the
enhancer I/X gene, nucleocapsid, and large surface antigen
promoters were transactivated in the presence of RXR and
PPAR [22]. Characterization of the nucleocapsid promoter
region demonstrated that HNF4 is the primary transcription
factor binding to the regulatory region spanning nucleotides
−127 to −102 whereas HNF4, RXR-PPAR heterodimers,
and chicken ovalbumin upstream promoter transcription
factor 1 (COUP-TF1) bind the regulatory region spanning
nucleotides −34 to −7[ 22]. Modulation of the level of
transcriptionfromthenucleocapsidpromoterbyRXR-PPAR
appears to be regulated by the regulatory sequence element
spanning nucleotides −34 to −7 and the HBV enhancer I
region (Figure 2). Another study demonstrated that HNF4
and testicular receptor 2 (TR2) repressed synthesis of the
pre-C RNA, whereas PPAR-RXR activated synthesis of the
pregenomicRNAandCOUP-TF1repressedsynthesisofboth
the pre-C and pregenomic RNAs [23].
The regulation of HBV transcription and regulation
were then explored in vivo. Using an HBV transgenic
mouse model, Guidotti et al. demonstrated that activation
of PPARα increased transcription and replication of HBV
and suggested that even a modest alteration in transcription
could have big impact on virus replication [24]. To point out
the importance of nuclear receptors and specially PPARα on
the HBV replication, Tang and McLachlan have shown that
ectopic expression of HNF4 and PPARα was necessary and
suﬃcienttoallowHBVreplicationinnonhepaticcells,which
is normally impossible due to the virus tropism [25].
Two studies performed in the team of McLachlan in
La Jolla speciﬁed the sequences of interaction between the
HBV and PPARα [26, 27]. Indeed, this team has developed
a transgenic mouse for a natural hepatitis B virus (HBV)
variant associated with seroconversion from HBeAg to anti-
HBe antibody that contains two nucleotide substitutions
(A1764T and G1766A) in the proximal nuclear hormone
receptor binding site in the nucleocapsid promoter. This
model suggested that peroxisome proliferators may enhance
viral transcription directly in a PPARα-dependent manner
through the nuclear hormone receptor recognition site in
the enhancer I region of the HBV genome. Moreover,
those mice transcribe very little precore RNA and secrete
extremely low levels of HBe antigen compared with the
wild-type HBV transgenic mice [26]. Analysis of HBV
transcription and replication in nonhepatoma cells indicates
that PPARα/RXRα heterodimers support higher levels of
pregenomicRNAtranscriptionfromthewild-typethanfrom
the variant nucleocapsid promoter, producing higher levels
of wild-type than of variant replication intermediates [27].
These observations indicate that the replication of wild-type
and variant viruses can be diﬀerentially regulated by the
liver-speciﬁc transcription factors that bind to the proximal
nuclear hormone receptor binding site of the nucleocapsid
promoter.
More recent data concern approaches to counteract this
nuclearreceptor-inducedHBVtranscriptionandreplication.4 PPAR Research
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Figure3:HBxproteincouldinﬂuenceliversteatosisthroughSREBP1
and PPARγ. Protein X of the HBV (HBx) increases the kinase
AKT phosphorylation and inhibits PTEN expression that leads
to increased expression and activation of SREBP1 in the liver. In
another way HBx enhances C/EBPα that in turn induces PPARγ
expression and activation. Both pathways lead to an increased
expression of adipogenic and lipogenic genes, which ﬁnally could
contribute to liver steatosis.
Oropeza et al. showed that the nuclear receptor short
heterodimer partner (SHP) inhibits the nuclear receptor-
mediated HBV replication [28]. HBV replication that is
dependent on HNF4 seemed considerably more sensitive to
SHP-mediated inhibition than PPARα/RXRα-directed viral
biosynthesis. A nonnucleosidic compound, Helioxanthin
(HE-145), was found to suppress HBV gene expression
and replication in HCC cells. It was found that HE-145
selectively suppresses surface antigen promoter II (SPII) and
core promoter (CP) but has no eﬀect on surface antigen
promoter I (SPI) or promoter for X gene (XP). Tseng et al.
showed that HE-145 acted by decreasing the DNA-binding
activity of PPAR to speciﬁc cis element of HBV promoter
for core antigen [29]. Taken together, all these data provide
an interesting rationale for modulating the PPARα/RXRα
heterodimer to control the HBV infection.
5.HBVModulatesPPARγ Expression:
Role in Steatosis
Until now, two studies described a role of HBx protein on
the regulation of PPARγ expression and activation and one of
which suggests a role in steatosis.
In the below paragraph, we have described the role of
PPAR on HBV transcription and replication. Conversely,
the HBx protein of HBV modulated PPARγ by protein-
protein interaction. Indeed, ligand activation of PPARγ has
been reported to induce growth inhibition and apoptosis in
various cancers including HCC. Choi and coll demonstrated
that HBx counteracted growth inhibition caused by PPARγ
ligand in HBx-associated HCC cells [30]. They found that
HBx bound to DNA binding domain of PPARγ and this
interaction blocked nuclear localization and binding to
PPRE. HBx signiﬁcantly suppressed the PPARγ mediated
transactivation.
More recent report described a positive eﬀect of HBx
protein on PPARγ expression and transcriptional activity
[31]. Some observations suggest that chronic HBV infection
is associated with hepatic steatosis, which is a common
histological feature of chronic infection with hepatitis C
virus [32]. Even if other report described lower frequency
of steatosis in hepatitis B [33, 34], evidence indicates that
hepatic steatosis is a more vulnerable factor that leads to
liver inﬂammation, ﬁbrosis, and cancer. Based on these
observations, Kim et al. demonstrated that overexpression
of HBx induced hepatic lipid accumulation [31]. This
phenomenon was accompanied by increased expression of
sterol regulatory element binding protein 1 (SREBP1) and
PPARγ. The authors proposed that HBx could participate to
hepaticsteatosisduringHBVinfectionbyregulatingSREBP1
and PPARγ expression and activation (Figure 3) but a direct
proof remains to be obtained.
6. Conclusion
HBV infection is a global health problem and recent
data indicate that the HBV DNA level is a strong risk
predictor of liver cirrhosis and HCC. Studies indicate the
presence of hormone response elements in the promoters
of HBV genome. Peroxisome proliferators may enhance
HBV viral transcription directly in a PPARα-dependent
manner. Conversely, HBx protein of HBV is able to induce
the gene expression and transcriptional activity of SREBP1
and PPARγ, thereby causing hepatic lipid accumulation by
increasing adipogenic and lipogenic gene expression. This
regulation loop between PPAR and HBV may contribute
to the progression of HBV-induced pathogenesis and the
development of PPAR antagonist could represent a new
therapeutic strategy.
Abbreviations
cccDNA: Covalently closed circular DNA
COUP-TF1: Chicken ovalbumin upstream promoter
transcription factor 1
HBV: Hepatitis B virus
HBcAg: Hepatitis B core antigen
HBeAg: Hepatitis B e antigen
HBsAg: Hepatitis B surface antigen
HCC: Hepatocellular carcinoma
HIV: Human immunodeﬁciency virus
HNF4: Hepatocyte nuclear factor 4
ORF: Open reading frame
PPAR: Peroxisome proliferator-activated receptor
RT: Reverse transcriptase enzyme
RXR: Retinoid X receptor
SHP: Short heterodimer partner
SREBP1: Sterol regulatory element binding protein 1
TR2: Testicular receptor 2PPAR Research 5
References
[1] A. S. Lok, “Chronic hepatitis B,” The New England Journal of
Medicine, vol. 346, no. 22, pp. 1682–1683, 2002.
[2] C.-J. Chen, H.-I. Yang, J. Su, et al., “Risk of hepatocellular
carcinoma across a biological gradient of serum hepatitis
B virus DNA Level,” T h eJ o u r n a lo ft h eA m e r i c a nM e d i c a l
Association, vol. 295, no. 1, pp. 65–73, 2006.
[3] C. Dreyer, G. Krey, H. Keller, F. Givel, G. Helftenbein, and W.
Wahli, “Control of the peroxisomal β-oxidation pathway by a
novel family of nuclear hormone receptors,” Cell, vol. 68, no.
5, pp. 879–887, 1992.
[4] D. J. Mangelsdorf, C. Thummel, M. Beato, et al., “The nuclear
receptor superfamily: the second decade,” Cell,v o l .8 3 ,n o .6 ,
pp. 835–839, 1995.
[5] D. Auboeuf, J. Rieusset, L. Fajas, et al., “Tissue distribution
and quantiﬁcation of the expression of mRNAs of peroxisome
proliferator-activated receptors and liver X receptor-α in
humans: no alteration in adipose tissue of obese and NIDDM
patients,” Diabetes, vol. 46, no. 8, pp. 1319–1327, 1997.
[ 6 ]C .N .A .P a l m e r ,M . - H .H s u ,K .J .G r i ﬃn, J. L. Raucy, and
E. F. Johnson, “Peroxisome proliferator-activated receptor-α
expression in human liver,” Molecular Pharmacology, vol. 53,
no. 1, pp. 14–22, 1998.
[7] S. M. Ulven, V. Natarajan, K. B. Holven, T. Løvdal, T. Berg,
and R. Blomhoﬀ, “Expression of retinoic acid receptor and
retinoid X receptor subtypes in rat liver cells: implications for
retinoid signalling in parenchymal, endothelial, Kupﬀer and
stellate cells,” E u r o p e a nJ o u r n a lo fC e l lB i o l o g y , vol. 77, no. 2,
pp. 111–116, 1998.
[ 8 ]J .K .R e d d y ,D .L .A z a r n o ﬀ, and C. E. Hignite, “Hypolipi-
daemic hepatic peroxisome proliferators form a novel class of
chemical carcinogens,” Nature, vol. 283, no. 5745, pp. 397–
398, 1980.
[9] T. Hashimoto, W. S. Cook, C. Qi, A. V. Yeldandi, J. K.
R e d d y ,a n dM .S .R a o ,“ D e f e c ti np e r o x i s o m ep r o l i f e r a t o r -
activated receptor α-inducible fatty acid oxidation determines
the severity of hepatic steatosis in response to fasting,” The
Journal of Biological Chemistry, vol. 275, no. 37, pp. 28918–
28928, 2000.
[10] S. P. Anderson, L. Yoon, E. B. Richard, C. S. Dunn, R.
C. Cattley, and J. C. Corton, “Delayed liver regeneration
in peroxisome proliferator-activated receptor-α-null mice,”
Hepatology, vol. 36, no. 3, pp. 544–554, 2002.
[ 1 1 ]Y . - J .Y .W a n ,M .M o r i m o t o ,R .G .T h u r m a n ,H .K .B o j e s ,
and S. W. French, “Expression of the peroxisome proliferator-
activated receptor gene is decreased in experimental alcoholic
liver disease,” Life Sciences, vol. 56, no. 5, pp. 307–317, 1995.
[12] S. Dharancy, M. Malapel, G. Perlemuter, et al., “Impaired
expression of the peroxisome proliferator-activated receptor
alphaduringhepatitisCvirusinfection,”Gastroenterology,vol.
128, no. 2, pp. 334–342, 2005.
[13] F. Andr´ e, “Hepatitis B epidemiology in Asia, the Middle East
and Africa,” Vaccine, vol. 18, supplement 1, pp. S20–S22, 2000.
[14] D. Lavanchy, “Worldwide epidemiology of HBV infection,
disease burden, and vaccine prevention,” Journal of Clinical
Virology, vol. 34, supplement 1, pp. S1–S3, 2005.
[15] Centers for Disease Control and Prevention (CDC),
“Progress in hepatitis B prevention through universal
infant vaccination—China, 1997–2006,” Morbidity and
Mortality Weekly Report, vol. 56, no. 18, pp. 441–445, 2007.
[ 1 6 ]R .A .C r o w t h e r ,N .A .K i s e l e v ,B .B ¨ ottcher, et al., “Three-
dimensional structure of hepatitis B virus core particles
determined by electron cryomicroscopy,” Cell,v o l .7 7 ,n o .6 ,
pp. 943–950, 1994.
[17] B. B¨ ottcher, S. A. Wynne, and R. A. Crowther, “Determination
of the fold of the core protein of hepatitis B virus by electron
cryomicroscopy,” Nature, vol. 386, no. 6620, pp. 88–91, 1997.
[18] K. Kuroki, F. Eng, T. Ishikawa, C. Turck, F. Harada, and
D. Ganem, “gp180, a host cell glycoprotein that binds duck
hepatitis B virus particles, is encoded by a member of
the carboxypeptidase gene family,” The Journal of Biological
Chemistry, vol. 270, no. 25, pp. 15022–15028, 1995.
[19] S. Urban, C. Schwarz, U. C. Marx, H. Zentgraf, H. Schaller,
and G. Multhaup, “Receptor recognition by a hepatitis B
virus reveals a novel mode of high aﬃnity virus-receptor
interaction,” The EMBO Journal, vol. 19, no. 6, pp. 1217–1227,
2000.
[20] J. Summers and W. S. Mason, “Replication of the genome of
a hepatitis B-like virus by reverse transcription of an RNA
intermediate,” Cell, vol. 29, no. 2, pp. 403–415, 1982.
[21] S. Locarnini, “Molecular virology of hepatitis B virus,”
Seminars in Liver Disease, vol. 24, supplement 1, pp. 3–10,
2004.
[ 2 2 ] A .K .R a n e y ,J .L .J o h n s o n ,C .N .A .P a l m e r ,a n dA .
Mclachlan, “Members of the nuclear receptor superfamily
regulate transcription from the hepatitis B virus nucleocapsid
promoter,” The Journal of Virology, vol. 71, no. 2, pp. 1058–
1071, 1997.
[ 2 3 ]X .Y ua n dJ .E .M e r t z ,“ D i ﬀerential regulation of the pre-
C and pregenomic promoters of human hepatitis B virus by
members of the nuclear receptor superfamily,” The Journal of
Virology, vol. 71, no. 12, pp. 9366–9374, 1997.
[24] L. G. Guidotti, C. M. Eggers, A. K. Raney, et al., “In vivo
regulation of hepatitis B virus replication by peroxisome
proliferators,” The Journal of Virology, vol. 73, no. 12, pp.
10377–10386, 1999.
[25] H. Tang and A. McLachlan, “Transcriptional regulation of
hepatitis B virus by nuclear hormone receptors is a critical
determinant of viral tropism,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 98, no.
4, pp. 1841–1846, 2001.
[26] A. K. Raney, E. F. Kline, H. Tang, and A. McLachlan,
“Transcription and replication of a natural hepatitis B virus
nucleocapsid promoter variant is regulated in vivo by perox-
isome proliferators,” Virology, vol. 289, no. 2, pp. 239–251,
2001.
[27] H. Tang, A. K. Raney, and A. McLachlan, “Replication of the
wild type and a natural hepatitis B virus nucleocapsid pro-
moter variant is diﬀerentially regulated by nuclear hormone
receptors in cell culture,” The Journal of Virology, vol. 75, no.
19, pp. 8937–8948, 2001.
[28] C. E. Oropeza, L. Li, and A. McLachlan, “Diﬀerential inhibi-
tion of nuclear hormone receptor-dependent hepatitis B virus
replication by the small heterodimer partner,” The Journal of
Virology, vol. 82, no. 8, pp. 3814–3821, 2008.
[29] Y. P. Tseng, Y. H. Kuo, C.-P. Hu, et al., “The role of heliox-
anthin in inhibiting human hepatitis B viral replication and
gene expression by interfering with the host transcriptional
machinery of viral promoters,” Antiviral Research, vol. 77, no.
3, pp. 206–214, 2008.
[30] Y.-H. Choi, H.-I. Kim, J. K. Seong, et al., “Hepatitis B virus X
protein modulates peroxisome proliferator-activated receptor
γ through protein-protein interaction,” FEBS Letters, vol. 557,
no. 1–3, pp. 73–80, 2004.
[31] K. H. Kim, H.-J. Shin, K. Kim, et al., “Hepatitis B virus X
protein induces hepatic steatosis via transcriptional activation6 PPAR Research
of SREBP1 and PPARγ,” Gastroenterology, vol. 132, no. 5, pp.
1955–1967, 2007.
[ 3 2 ]A .G o r d o n ,C .A .M c L e a n ,J .S .P e d e r s e n ,M .J .B a i l e y ,a n d
S. K. Roberts, “Hepatic steatosis in chronic hepatitis B and
C: predictors, distribution and eﬀect on ﬁbrosis,” Journal of
Hepatology, vol. 43, no. 1, pp. 38–44, 2005.
[33] R. Moucari, T. Asselah, D. Cazals-Hatem, et al., “Insulin resis-
tance in chronic hepatitis C: association with genotypes 1 and
4, serum HCV RNA level, and liver ﬁbrosis,” Gastroenterology,
vol. 134, no. 2, pp. 416–423, 2008.
[34] G.L.-H.Wong,V.W.-S.Wong,P.C.-L.Choi,etal.,“Metabolic
syndrome increases the risk of liver cirrhosis in chronic
hepatitis B,” Gut, vol. 58, no. 1, pp. 111–117, 2009.